Common Stock, $0.0001 par value per share
- Symbol
- KYMR
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Kymera Therapeutics, Inc.
KYMRNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition On October 29, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.…
Company context
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Current securities
Registered securities in this filing
KYMERA THERAPEUTICS, INC. · 8-K · Filed 2026-10-29
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition
On October 29, 2026, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial KT-579 (IRF5) Phase 1 healthy volunteer data demonstrated deep, sustained IRF5 degradation, robust modulation of disease-relevant biomarkers and a favorable safety profile KT-579 LUMORA Phase 1b trial in lupus patients planned to start by early 2027 Last patient completed last visit in KT-621 (STAT6) BROADEN2 Phase 2b AD trial, with topline data to be reported by year-end 2026 KT-621 BREADTH Phase 2b asthma trial ongoing, with topline data expected to be reported in late 2027 Well-capitalized with $1.6 billion in cash as of September 30, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET Watertown, Mass. (October 29, 2026) - Kymera Therapeutics, Inc.(NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today reported financial results for the third quarter ended September 30, 2026, and provided business highlights and updates on its pipeline. “Kymera’s recent progress reinforc…
Open exhibit ↗